

Qty: 100µg/400 µL Rabbit anti-LRP5 Catalog No. 36-5400 Lot No.

Rabbit anti-LRP5

FORM

This polyclonal antibody is supplied as a 400 µL aliquot at a concentration of 0.25 mg/mL in phosphate buffered saline (pH 7.4) containing 0.1% sodium azide. This antibody is epitope-affinity purified from rabbit antiserum.

PAD: ZMD.358

IMMUNOGEN

Synthetic peptide derived from the C-terminal region of the human LRP5 protein. This intracellular region is identical to the corresponding mouse and rat LRP5 amino acid sequences.

SPECIFICITY

This antibody reacts with human and mouse LRP5 proteins. On Western blots, it identifies a single band at ~200 kDa. Western blot tests using negative control mock pSEC-tag-transfected 293T cell lysates did not yield the target band.

REACTIVITY

Reactivity has been confirmed with mouse LRP5-pSEC-tag-transfected 293T cells, MCF-7 human breast adenocarcinoma, T47D human breast ductal carcinoma, and NIH-3T3 mouse embryo fibroblast lysates.

| Sample | Western Blotting | Immunofluorescence | Immuno- precipitation |
|--------|---------------------|--------------------|--------------------------|
| Human | +++ | ND | 0 |
| Mouse | +++ | +++ | 0 |
| Rat | ND | ND | ND |

(Excellent +++, Good++, Poor +, No reactivity 0, Not applicable N/A, Not Determined ND)

USAGE

Working concentrations for specific applications should be determined by the investigator. Appropriate concentrations will be affected by several factors, including secondary antibody affinity, antigen concentration, sensitivity of detection method, temperature and length of incubations, etc. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.

| Western Blotting: | 1-3 µg/mL |
|---------------------|-----------|
| Immunofluorescence: | 2-3 µg/mL |

NOTE: For optimal results in immunofluorescence assays, cells should be fixed in 4% paraformaldehyde/0.5% Triton X-100/PBS for 10 minutes, permeabilized with 0.5% Triton X-100/PBS for 5 minutes, and blocked with 5% BSA/PBS for 30 minutes.

STORAGE

PI365400

Store at 2-8°C for up to one month. Store at -20°C for long-term storage. Avoid repeated freezing and thawing.

(cont'd)

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

(Rev 10/08) DCC-08-1089

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, <u>www.invitrogen.com</u>). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

(Rev 10/08) DCC-08-1089

BACKGROUND

WNT proteins have diverse roles in governing cell fate, proliferation, migration, porarity and death. WNT signaling controls development and is important for embryogenesis and carcinogenesis¹⁻³. WNTs are transduced through at least three distinct intracellular signaling pathways including the canonical 'WNT/ β -catenin', 'WNT/Ca²⁺, and 'WNT' polarity (also called the 'planar polarity' pathway)^{2, 4,5} pathways.

LRP5 (Low Density Lipoprotein Receptor-related Protein 5) is a member of the LDL receptor family, binds apolipoprotein E, and is widely expressed in many tissues, including hepatocytes, adrenal gland, and pancreas.⁶ LRP5 functions as a WNT co-receptor and interacts with Frizzled receptors. LRP5 is important in embryonic development, bone accrual development, eye development, normal cholesterol metabolism, and glucose-induced insulin secretion.⁶ Expression of LRP5 has also been used as a novel marker for disease progression in high-grade osteosarcoma.⁷

REFERENCES

- 1. Cadigan KM and Nusse R. Genes Dev 11:3286-3305, 1997.
- 2. Miller JR, et al. Oncogene 18:7860-7872, 1999.
- 3. Polakis P. Genes Dev 14:1837-1851, 2000.
- 4. Adler, PN and Lee H. Curr Opin Cell Biol 13:635-640, 2001.
- 5. Kuhl M, et al. Trends Genet 16:279-283, 2000.
- 6. Magoori K, et al. J Biol Chem 278(13): 11331-11336, 2003.
- 7. Hoang BH, et al. Int J Cancer 109(1): 106-11, 2004.

RELATED PRODUCTS

PI365400

| Conjugate | ZyMAX™ Goat x Rabbit IgG (H+L) | ZyMAX™ Goat x Mouse IgG (H+L) |
|-----------|-----------------------------------|----------------------------------|
| Purified | 81-6100 | 81-6500 |
| FITC | 81-6111 | 81-6511 |
| TRITC | 81-6114 | 81-6514 |
| Cy™3 | 81-6115 | 81-6515 |
| Cy™5 | 81-6116 | 81-6516 |
| HRP | 81-6120 | 81-6520 |
| AP | 81-6122 | 81-6522 |
| Biotin | 81-6140 | 81-6540 |

Zymed[®] and ZyMAX[™] are trademarks of Zymed Laboratories Inc. Cy[™] and Sepharose[®] are trademarks of Amersham Biosciences Ltd.

For Research Use Only

www.invitrogen.com

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com